U.S. FDA Approves ViiV Healthcare’s Tivicay PD for HIV Treatment in Pediatric Patients Weighing at Least 2 kg
RegulatoryapprovedTivicay PDPositive
AI Analysis
Summary
The FDA has approved ViiV Healthcare's Tivicay PD (dolutegravir) for HIV treatment in pediatric patients weighing at least 2 kg. This regulatory approval expands the drug's pediatric indication in the U.S. market.
Outcome Details
FDA approval for pediatric patients weighing at least 2 kg
Importance:8/10
Sentiment:
0.90
FDA approvalHIVpediatric indicationViiV Healthcaredolutegravir
Read the original article
Published by Drugs.com New Drug Approvals on August 26, 2026 3:08 AM